Eli Lilly and Company

LLY · NYSE

Eli Lilly reported FY2025 revenue of $65.2 billion and 2026 Q1 revenue of $19.8 billion. The thesis depends on tirzepatide demand, manufacturing capacity, pipeline reinvestment and cash conversion.

Follow Add to Watchlist Ask Question

NYSE LLY Coverage Bootstrap Eli Lilly and Company

Latest ReportMay 19, 2026Eli Lilly: obesity-drug scale is now a manufacturing and cash-conversion testView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

NYSE

Clear tags

Latest Thesis

Eli Lilly: obesity-drug scale is now a manufacturing and cash-conversion test

Eli Lilly reported FY2025 revenue of $65.2 billion and 2026 Q1 revenue of $19.8 billion. The thesis depends on tirzepatide demand, manufacturing capacity, pipeline reinvestment and cash conversion.

May 19, 2026Research reportSlides available

Read report Open slides Discussion (0)

Eli Lilly and CompanyLilly: obesity-drug scale is now a manufacturing and cash-converMay 19, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->